GARDP global network
Based in Geneva, GARDP is committed to carrying out antibiotic R&D in regions heavily affected by drug resistance and to ensuring that approved treatments in our portfolio reach patients in those regions. With our co-founder and alliance partner DNDi, we have a cost-efficient global network.
GARDP teams are currently hosted in several locations worldwide through DNDi, including Brazil, India, Japan and Thailand. To advance engagement in Africa, an independent collaborative entity known as DNDi GARDP Southern Africa Plc (DGSA) was established in South Africa in 2018. GARDP North America Inc., also an independent organization, was established in 2021. We will continue to increase our presence in key geographies which support our clinical trials and access activities.
GARDP’s team is strategically located to facilitate partnerships with research and healthcare institutions in India, South Africa, and other countries that are heavily affected by drug resistance.
GARDP collaborates with R&D institutions around the world, drawing on local expertise and skills and expanding local capacity as needed for current and future clinical research.
An alliance agreement with DNDi enables GARDP to support its team in key regions throughout the world without significant increases in overhead costs.
Established by DNDi and GARDP in 2018, DGSA is an independent organization responsible for the implementation of GARDP’s trials in Southern Africa. The team also builds regional networks for advocacy, access and stewardship strategies for antibiotics, including SECURE.
Established in the US in 2021, this 501c3 public charity organization aims to increase awareness, raise funds and advocate for policy change to counter AMR.
GARDP is hosted in Japan by DNDi. This team liaises with Japanese pharmaceuticals, research partners and the Japanese government.